Page last updated: 2024-10-28

guaifenesin and Sleep Apnea, Obstructive

guaifenesin has been researched along with Sleep Apnea, Obstructive in 4 studies

Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Raff, H1
Ettema, SL1
Eastwood, DC1
Woodson, BT1
Wan, N1
Tang, X1
Ding, H1
Yan, Y1
Zhuang, Y1
Qi, C1
Chen, Q1
Xie, W1
Zhang, J1
Wang, Y1
Liang, M1
Ning, W1
Cao, J1
Winther, B1
Gross, BC1
Hendley, JO1
Early, SV1
Schmidt, HJ1
Bhandari, V1
Bhandari, A1
Davies, J1
Marshall, BC1
Praud, JP1
Zar, HJ1
Rubin, BK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea[NCT01196117]18 participants (Actual)Interventional2004-11-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Epworth Sleepiness Score (ESS)

Epworth Sleepiness Score (ESS) is a scale to assess sleepiness during waking hours. The scale ranges from 0-24 with higher scores indicative of greater sleepiness. (NCT01196117)
Timeframe: Difference between Baseline(Day 0) and Average of Day 1,7,14.

Interventionunits on a scale (Median)
14 Days of Placebo Therapy, Then CPAP10.7
14 Days of CPAP Therapy8.9

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~ 7am, Day 7

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 7am

Interventionnmol/l (Mean)
CPAP>= 3 Hours Per Night9.9
CPAP<3 Hours Per Night13.3

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 0

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 11pm

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night3.2
CPAP<3 Hours Per Night1.2

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 1

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 11pm

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night2.2
CPAP<3 Hours Per Night1.8

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 14

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 11pm

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night1.9
CPAP<3 Hours Per Night2.2

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 7

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 11pm

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night3.0
CPAP<3 Hours Per Night2.5

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 0

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 7am

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night12.5
CPAP<3 Hours Per Night12.1

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 1

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 7am

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night7.4
CPAP<3 Hours Per Night13.6

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 14

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 7am

Interventionnmol/l (Median)
CPAP>= 3 Hours Per Night9.2
CPAP<3 Hours Per Night15.0

Reviews

1 review available for guaifenesin and Sleep Apnea, Obstructive

ArticleYear
The future in paediatric respirology.
    Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:5

    Topics: Adult; Asthma; Bronchopulmonary Dysplasia; Child; Chronic Disease; Cystic Fibrosis; Humans; Infant,

2010

Trials

1 trial available for guaifenesin and Sleep Apnea, Obstructive

ArticleYear
Salivary cortisol in obstructive sleep apnea: the effect of CPAP.
    Endocrine, 2011, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Continuous Positive Airway Pressure; Expecto

2011

Other Studies

2 other studies available for guaifenesin and Sleep Apnea, Obstructive

ArticleYear
Influence of coexistence of mild OSA on airway mucus hypersecretion in patients with COPD.
    Journal of breath research, 2021, 02-01, Volume: 15, Issue:2

    Topics: Breath Tests; Epithelial Cells; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Sleep Apnea,

2021
Location of bacterial biofilm in the mucus overlying the adenoid by light microscopy.
    Archives of otolaryngology--head & neck surgery, 2009, Volume: 135, Issue:12

    Topics: Adenoids; Bacteria; Biofilms; Child; Chronic Disease; Coloring Agents; Humans; In Situ Hybridization

2009